ATE544762T1 - Calcium rezeptor modulatoren - Google Patents

Calcium rezeptor modulatoren

Info

Publication number
ATE544762T1
ATE544762T1 AT03736701T AT03736701T ATE544762T1 AT E544762 T1 ATE544762 T1 AT E544762T1 AT 03736701 T AT03736701 T AT 03736701T AT 03736701 T AT03736701 T AT 03736701T AT E544762 T1 ATE544762 T1 AT E544762T1
Authority
AT
Austria
Prior art keywords
receptor modulators
calcium receptor
calcium
modulators
receptor
Prior art date
Application number
AT03736701T
Other languages
English (en)
Inventor
Michael Kelly
Shimin Xu
Ning Xi
Robert Townsend
David Semin
Chiara Ghiron
Thomas Coutler
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE544762T1 publication Critical patent/ATE544762T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/86Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AT03736701T 2002-05-23 2003-05-23 Calcium rezeptor modulatoren ATE544762T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38327002P 2002-05-23 2002-05-23
US10/444,945 US7176322B2 (en) 2002-05-23 2003-05-22 Calcium receptor modulating agents
PCT/US2003/016384 WO2003099814A1 (en) 2002-05-23 2003-05-23 Calcium receptor modulating agents

Publications (1)

Publication Number Publication Date
ATE544762T1 true ATE544762T1 (de) 2012-02-15

Family

ID=29586996

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03736701T ATE544762T1 (de) 2002-05-23 2003-05-23 Calcium rezeptor modulatoren

Country Status (12)

Country Link
US (1) US7176322B2 (de)
EP (1) EP1509518B1 (de)
JP (1) JP4642461B2 (de)
AR (1) AR040095A1 (de)
AT (1) ATE544762T1 (de)
AU (1) AU2003237235B2 (de)
CA (1) CA2485685C (de)
ES (1) ES2378759T3 (de)
MX (1) MXPA04011469A (de)
PL (1) PL375559A1 (de)
TW (1) TW200410960A (de)
WO (1) WO2003099814A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908935B2 (en) * 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
WO2005065050A2 (ja) * 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation 2環化合物
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
ES2561111T3 (es) * 2004-05-28 2016-02-24 Mitsubishi Tanabe Pharma Corporation Arilalquilaminas y procedimiento para la producción de las mismas
US7361789B1 (en) 2004-07-28 2008-04-22 Amgen Inc. Dihydronaphthalene compounds, compositions, uses thereof, and methods for synthesis
CA2608957C (en) * 2005-05-19 2013-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
WO2007027548A2 (en) * 2005-09-02 2007-03-08 Amgen Inc. Methods of modulating intestinal fluid balance
US20070287707A1 (en) * 2006-02-28 2007-12-13 Arrington Mark P Phosphodiesterase 10 inhibitors
CA2645494C (en) * 2006-03-23 2016-01-12 Amgen Inc. Methods and compositions for making and using polymorphs of cinacalcet
EP2010150A2 (de) * 2006-04-20 2009-01-07 Amgen Inc. Stabile emulsionsformulierungen
US8093299B2 (en) 2007-03-30 2012-01-10 Amgen Inc. Methods of treating bowel disorders
WO2009051718A2 (en) * 2007-10-15 2009-04-23 Amgen Inc. Calcium receptor modulating agents
WO2009155527A2 (en) * 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
EP2435404A1 (de) 2009-05-27 2012-04-04 Leo Pharma A/S Neue, calciumempfindliche rezeptoren modulierende verbindungen und deren pharmazeutische verwendung
EP2435400A2 (de) 2009-05-27 2012-04-04 Leo Pharma A/S Neue, den calcium sensing receptor modulierende verbindungen und deren pharmazeutische verwendung
RU2599788C2 (ru) 2010-06-30 2016-10-20 Лео Фарма А/С Новая полиморфная форма кальцимиметического соединения
RU2599789C2 (ru) 2010-06-30 2016-10-20 Лео Фарма А/С Новая полиморфная форма кальцимиметического соединения
WO2012069419A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
JP2014508104A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
EP2643298A1 (de) 2010-11-26 2013-10-02 Leo Pharma A/S Substituierte cyclopentylazine als casr-aktive verbindungen
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
CA2882039A1 (en) * 2012-08-27 2014-03-06 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN105120863B (zh) 2013-03-14 2021-06-04 奥斯特克有限公司 促进骨生长的烷基胺骆驼蓬碱衍生物
CN113166058A (zh) 2018-08-14 2021-07-23 奥斯特克有限公司 氟β-咔啉化合物
ES3004565T3 (en) 2018-08-14 2025-03-12 Ossifi Therapeutics Llc Pyrrolo - dipyridine compounds for the treatment of bone loss

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US444946A (en) * 1891-01-20 Method of electric welding
US143212A (en) * 1873-09-23 Improvement in attachments for ladies work-tables
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
ES2256370T3 (es) 1991-08-23 2006-07-16 Nps Pharmaceuticals, Inc. Moleculas activas para el receptor de calcio.
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
DK0724561T3 (da) 1991-08-23 2004-06-28 Nps Pharma Inc Calciumreceptoraktive arylalkylaminer
DE69333527T2 (de) 1993-02-23 2005-06-16 Brigham & Women's Hospital, Inc., Boston Calciumrezeptoraktive moleküle
AU3414295A (en) 1994-08-19 1996-03-14 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
WO1996009818A1 (en) 1994-09-27 1996-04-04 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
CN1147459C (zh) * 1994-10-21 2004-04-28 Nps药物有限公司 钙受体活性化合物
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
JPH10507934A (ja) 1995-07-26 1998-08-04 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド 代謝指向型グルタミン酸受容体に活性を示す化合物を同定するためのキメラ受容体および方法、ならびに神経学的障害および疾患の治療におけるそのような化合物の使用
AU726659B2 (en) 1996-04-09 2000-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
ATE430123T1 (de) 1996-05-01 2009-05-15 Nps Pharma Inc Inorganische am ionen-rezeptor aktive verbindungen
ES2364179T3 (es) 1996-07-08 2011-08-26 Kyowa Hakko Kirin Co., Ltd. Compuestos con actividad receptora de calcio.
HU228509B1 (en) 1997-02-21 2013-03-28 Bayer Ip Gmbh Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
US6103737A (en) 1997-07-03 2000-08-15 Dupont Pharmaceuticals Company Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists
US6335338B1 (en) 1998-08-12 2002-01-01 Smithkline Beecham Corporation Calcilytic compounds
CA2347092A1 (en) 1998-10-14 2000-04-20 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
CN1131212C (zh) 1999-02-24 2003-12-17 弗·哈夫曼-拉罗切有限公司 苯基-和吡啶基衍生物
CN1134417C (zh) 1999-02-24 2004-01-14 弗·哈夫曼-拉罗切有限公司 3-苯基吡啶衍生物及其作为nk-1受体拮抗剂的应用
EP1074539B1 (de) 1999-08-04 2007-10-17 Sumitomo Chemical Company, Limited Verfahren zur Herstellung von optisch aktiver 3,3,3-Trifluor-2-hydroxy-2-methylpropionsäure und deren Salze
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
EP1116711B1 (de) 1999-12-18 2005-12-14 Wella Aktiengesellschaft 2-Aminoalkyl-1,4-diaminobenzol-Derivate und diese Verbindungen enthaltende Färbemittel
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
WO2001096307A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
WO2002051805A1 (de) 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indol-derivate
CA2448160A1 (en) * 2001-05-25 2002-12-05 Queen's University At Kingston Heterocyclic beta-amino acids and their use as anti-epileptogenic agents

Also Published As

Publication number Publication date
PL375559A1 (en) 2005-11-28
US7176322B2 (en) 2007-02-13
AR040095A1 (es) 2005-03-16
AU2003237235A1 (en) 2003-12-12
CA2485685C (en) 2010-02-02
US20040077619A1 (en) 2004-04-22
EP1509518A1 (de) 2005-03-02
JP4642461B2 (ja) 2011-03-02
WO2003099814A1 (en) 2003-12-04
JP2005530811A (ja) 2005-10-13
TW200410960A (en) 2004-07-01
MXPA04011469A (es) 2005-02-14
CA2485685A1 (en) 2003-12-04
AU2003237235B2 (en) 2007-08-23
EP1509518B1 (de) 2012-02-08
ES2378759T3 (es) 2012-04-17

Similar Documents

Publication Publication Date Title
ATE544762T1 (de) Calcium rezeptor modulatoren
FI20020800A7 (fi) Modulaattori
ATE416168T1 (de) Modulatoren des vanilloidrezeptors
ATE557036T1 (de) Ox40 rezeptor bindende agenzien
DE50206171D1 (de) Knochenverankerungselement
AU2003290778A8 (en) Non-steroidal farnesoid x receptor modulators
DK1569712T3 (da) Forbindelsesindretning
DE60327767D1 (de) Tricyclische steroidhormonkernrezeptor-modulatoren
DE602004026540D1 (de) Kurbelwellenmomentmodulator
PL382706A1 (pl) Związek modulujący receptor wapnia i jego zastosowanie
PL376438A1 (en) Calcium receptor modulating arylalkylamines
DE60336314D1 (de) Substituierte indole
ATE456558T1 (de) Gabanerge modulatoren
ATA10102002A (de) Gewebeband-einrichtung
DE50206709D1 (de) Knochenplatte
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
DE60335913D1 (de) Ghrelin-analoga
DE60327447D1 (de) Pflaster
DE50312759D1 (de) Oszillationsantrieb
DE602004018247D1 (de) Modulator
FI20020258A0 (fi) Kiristyselin
DE50313381D1 (de) Oszillationsantrieb
DK1495030T3 (da) Ikke-steroidale progesteronreceptormodulatorer
DE50307407D1 (de) Strömungsbremse
NO20022892L (no) Forankringssystem